A phase III multicenter study of intratumoral/interstitial therapy with TransMID [XR 311] compared to best standard of care in patients with progressive and/or recurrent, non-resectable glioblastoma multiforme.
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2010
At a glance
- Drugs XR 311 (Primary) ; Antineoplastics
- Indications Glioblastoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Sep 2005 New trial record.